This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC). The trial is designed to investigate VB10.16, an investigational therapeutic DNA vaccine in combination with another medicine, pembrolizumab, which is the standard of care for patients with previously untreated metastatic or resectable recurrent PD-L1 positive HNSCC. The study is divided in 2 parts: * Phase 1: Dose escalation to evaluate safety and determine the recommended phase 2 dose (RP2D) of VB10.16 * Phase 2: Randomized comparison of VB10.16 in combination with pembrolizumab versus pembrolizumab monotherapy The goal of Phase 1 is to evaluate the safety and tolerability of the combined treatment and to decide on the dose of VB10.16 to be used in the second part of the trial. The randomized Phase 2 will consist of 2 parallel arms exploring VB10.16 at the selected RP2D from the escalation phase in combination with pembrolizumab SoC (experimental arm, Arm A), versus pembrolizumab alone (control arm, Arm B).
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 8 years. 2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met. 3. The visit frequency will be every 3 weeks during the treatment period. Note: Participants on osimertinib treatment(osimertinib only arm or who have discontinued Dato-DXd while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression or IP discontinuation. Participants who are receiving osimertinib + Dato-DXd are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
About the trial
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosłe kobiety (przed, w trakcie lub po menopauzie) i dorosłych mężczyźni
- •Potwierdzony histologicznie rak piersi dodatni na receptory hormonów (HR+) i ujemny na HER2, na podstawie najnowszej próbki nowotworu
- •Kwalifikacja do terapii fulwestrantem i co najmniej jednym z leków: palbociklib, rybociklib lub abemaciklib
- •Prawidłowe funkcje organów wewnętrznych i szpiku kostnego
- •Zgoda na dostarczenie obowiązkowej próbki nowotworu
✗ Disqualifies
- •Historia innego pierwotnego nowotworu (z wyjątkiem wyleczonego co najmniej 2 lata przed badaniem)
- •Radioterapia w ciągu 2 tygodni przed rozpoczęciem badania
- •Poważna operacja lub uraz w ciągu 4 tygodni przed rozpoczęciem badania
- •Utrzymujące się działania niepożądane z poprzedniej chemioterapii (stopień wyższy niż 1)
- •Uciśnięcie rdzenia kręgowego, przerzuty do mózgu lub opon mózgowych
- •Zaburzenia czynności serca w chwili badania początkowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (225)
Research Site
Tucson, United States
Research Site
Fountain Valley, United States
Research Site
Glendale, United States
Research Site
Los Angeles, United States
Research Site
Napa, United States
Research Site
San Francisco, United States
Research Site
Santa Rosa, United States
Research Site
Aurora, United States
Research Site
New Haven, United States
Research Site
Newark, United States
Research Site
Louisville, United States
Research Site
Annapolis, United States
Research Site
Boston, United States
Research Site
Detroit, United States
Research Site
Grand Rapids, United States
Research Site
Hannibal, United States
Research Site
St Louis, United States
Research Site
Omaha, United States
Research Site
Camden, United States
Research Site
Mineola, United States
Research Site
New York, United States
Research Site
New York, United States
Research Site
Gresham, United States
Research Site
Philadelphia, United States
Research Site
Pittsburgh, United States
Research Site
York, United States
Research Site
Greenville, United States
Research Site
Chattanooga, United States
Research Site
Nashville, United States
Research Site
Dallas, United States
Research Site
Houston, United States
Research Site
Irving, United States
Research Site
San Antonio, United States
Research Site
San Antonio, United States
Research Site
Salt Lake City, United States
Research Site
Fairfax, United States
Research Site
Falls Church, United States
Research Site
Midlothian, United States
Research Site
Norfolk, United States
Research Site
Tacoma, United States
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Chivilcoy, Argentina
Research Site
Rosario, Argentina
Research Site
Darlinghurst, Australia
Research Site
Nedlands, Australia
Research Site
Waratah, Australia
Research Site
Brasschaat, Belgium
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Haine-Saint-Paul, Belgium
Research Site
Leuven, Belgium
Research Site
Alfenas, Brazil
Research Site
Blumenau, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Velho, Brazil
Research Site
São Paulo, Brazil
Research Site
Taubaté, Brazil
Research Site
Teresina, Brazil
Research Site
Vitória, Brazil
Research Site
Abbotsford British Columbia, Canada
Research Site
Kelowna, Canada
Research Site
Halifax, Canada
Research Site
Brampton, Canada
Research Site
Ottawa, Canada
Research Site
Toronto, Canada
Research Site
Sherbrooke, Canada
Research Site
Chicoutimi, Canada
Research Site
Montreal, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Nanchang, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanning, China
Research Site
Shandong, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenyang, China
Research Site
Ürümqi, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Xuzhou, China
Research Site
Zhengzhou, China
Research Site
Aalborg, Denmark
Research Site
Aarhus N, Denmark
Research Site
Hillerød, Denmark
Research Site
Odense, Denmark
Research Site
Bobigny, France
Research Site
Limoges, France
Research Site
Lyon, France
Research Site
Plérin, France
Research Site
Rouen, France
Research Site
Saint-Herblain, France
Research Site
Villejuif, France
Research Site
Augsburg, Germany
Research Site
Dresden, Germany
Research Site
Erlangen, Germany
Research Site
Essen, Germany
Research Site
Frankfurt am Main, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Georgsmarienhütte, Germany
Research Site
Hanover, Germany
Research Site
Heilbronn, Germany
Research Site
Kiel, Germany
Research Site
Leipzig, Germany
Research Site
Mannheim, Germany
Research Site
Mönchengladbach, Germany
Research Site
Regensburg, Germany
Research Site
Ulm, Germany
Research Site
Bangalore, India
Research Site
Mohali, India
Research Site
Mysuru, India
Research Site
Nagpur, India
Research Site
New Delhi, India
Research Site
New Delhi, India
Research Site
Vadodara, India
Research Site
Varanasi, India
Research Site
Bologna, Italy
Research Site
Florence, Italy
Research Site
Misterbianco, Italy
Research Site
Naples, Italy
Research Site
Padova, Italy
Research Site
Prato, Italy
Research Site
Roma, Italy
Research Site
Chiba, Japan
Research Site
Chūōku, Japan
Research Site
Chūōku, Japan
Research Site
Hidaka-shi, Japan
Research Site
Hiroshima, Japan
Research Site
Isehara-shi, Japan
Research Site
Kagoshima, Japan
Research Site
Kōtoku, Japan
Research Site
Kyoto, Japan
Research Site
Matsuyama, Japan
Research Site
Naha, Japan
Research Site
Osaka, Japan
Research Site
Ota-shi, Japan
Research Site
Sapporo, Japan
Research Site
Sendai, Japan
Research Site
Shimotsuke-shi, Japan
Research Site
Shinagawa-ku, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Suita-shi, Japan
Research Site
Takasaki-shi, Japan
Research Site
Tsu, Japan
Research Site
Yokohama, Japan
Research Site
George Town, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuala Selangor, Malaysia
Research Site
Kuala Selangor, Malaysia
Research Site
Kuching, Malaysia
Research Site
Pulau Pinang, Malaysia
Research Site
Bydgoszcz, Poland
Research Site
Krakow, Poland
Research Site
Warsaw, Poland
Research Site
Goyang-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Granada, Spain
Research Site
Lleida, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Pamplona, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Lund, Sweden
Research Site
Solna, Sweden
Research Site
Kaohsiung City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Dusit, Thailand
Research Site
Hat Yai, Thailand
Research Site
Khon Kaen, Thailand
Research Site
Lampang, Thailand
Research Site
Ratchathewi, Thailand
Research Site
Ankara, Turkey (Türkiye)
Research Site
Antalya, Turkey (Türkiye)
Research Site
Cordaleo, Turkey (Türkiye)
Research Site
Goztepe Istanbul, Turkey (Türkiye)
Research Site
Malatya, Turkey (Türkiye)
Research Site
Samsun, Turkey (Türkiye)
Research Site
Guildford, United Kingdom
Research Site
London, United Kingdom
Research Site
Londonderry, United Kingdom
Research Site
Taunton, United Kingdom
Research Site
York, United Kingdom
Research Site
Can Tho, Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Research Site
Hồ Chí Minh, Vietnam
Research Site
Vinh, Vietnam
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.